Troels Jordansen | Chief Executive Officer
Glycostem

Troels Jordansen, Chief Executive Officer, Glycostem

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 14:20

Building your own closed manufacturing system

Conference Day 2 - Wednesday 1st April 2020 @ 17:40

World’s first off-the-shelf NK cellular immunotherapy making cancer a chronic disease

last published: 05/Dec/19 09:46 GMT

back to speakers